The growing recognition of serious neurological damage happening to people who were infected with COVID 19 is now growing and scientific findings are struggling to answer the question as to its viral or inflammatory cause. Treatment choices will turn on the underlying causative factors but the need for a quick and safe treatment is considerable now. I can speak from my personal experience with having had CV19 starting in late March and being tested as free of virus in late April about the impact this illness can have on neurological functioning. I had several spike of fever to above 103F and severe chills and productive cough and fatigue. I thought originally I had pneumonia until the test proved it was CV19. My neurological symptoms included ataxia, impaired cognition and was occasionally unable to organize my communication adequately, particularly with word finding and auditory processing.
I was fortunately had the Cognitolite 1068nm pulsed (10hz) transcranial infrared unit at home and used it 2-4x daily for well over a month and then tapered to 3-5x/week now. I also was taking 2G VitC q2hr and tapering by half when my urine turned bright yellow. I never had GI distress during this period of high dosing nor afterward. I also was taking 5-10K D3 and Zinc daily and flushing my system with filtered water and electrolytes.
It would seem likely that my symptom severity was decreased by this regime and it would now seem reasonable from further investigation that the use of transcranial photobiomodulation could be used as an initial intervention with minimal side effect potential while patients are evaluated for viral or parasitic and other neuroinflammatory markers that would indicate the need for antiviral or anti-inflammatory treatment.
Quietmind Fdn. is making the Cognitolite treatment is available for home use by rental of the device on a donation basis. Please call 610-940-0488 to discuss the protocol.
With the publication of this study jamanetwork.com/journals/jamanetworkopen/fullarticle/2770551, we are now entering a new level of recognition for the use of light therapy for treating neurodegenerative diseases and neurotrauma rehabilitation. The use of transcranial light therapy in treating TBI is now showing to be safe, easily tolerated and effective in making measurable changes in brain physiology. These findings are welcome addition to the published research and clinical programs at Quietmind Fdn. over the past 13 years with the Cognitolite and for 6 years with Vielight's Neuro photobiomodulation devices. We are conducting ongoing trials with Vielight's devices and can offer participants substantial savings and free clinical assessments.
Our hope is to advance further with these techniques and hope to collaborate with the team at Harvard and elsewhere on designing new integrated tools that will deliver the correct amount of light to produce the optimal cognitive and physical responses for people with head trauma and neurodegenerative disorders like Alzheimer's, Parkinson's and ALS. More information on our current clinical trials can be found at www.quietmindfdn.org/trials.html
Recent work done in clinics in the US have shown that exposure to green light in the prodromal (early) stages of migraines can significantly reduce their severity. This report provided by Kaiyam Medical. I think this would be good to combine with neurofeedback to rework the CNS' response to stimulation.
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.